Afinitor approved in Europe for pancreatic NETs
This article was originally published in Scrip
Executive Summary
The European Commission has approved Novartis' mTOR inhibitor Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours (NET) of pancreatic origin in adults with progressive disease.